R Cioffi

828 total citations
27 papers, 621 citations indexed

About

R Cioffi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, R Cioffi has authored 27 papers receiving a total of 621 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in R Cioffi's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (15 papers) and Cancer Treatment and Pharmacology (9 papers). R Cioffi is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (15 papers) and Cancer Treatment and Pharmacology (9 papers). R Cioffi collaborates with scholars based in Italy, United States and United Kingdom. R Cioffi's co-authors include G. Frasci, Luigi Maiorino, Luigi Manzione, Domenico Bilancia, G.P. Nicolella, Pasquale Comella, Giuseppe De Cataldis, Gianfranco Filippelli, Michele Greco and Enrico Tedeschi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

R Cioffi

27 papers receiving 603 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R Cioffi Italy 13 485 423 102 70 60 27 621
G.P. Nicolella Italy 10 622 1.3× 634 1.5× 116 1.1× 38 0.5× 65 1.1× 21 818
Michèle Natale Germany 8 256 0.5× 293 0.7× 86 0.8× 27 0.4× 50 0.8× 25 415
Swee‐Peng Yap Singapore 7 255 0.5× 287 0.7× 100 1.0× 45 0.6× 80 1.3× 9 532
Woo Kun Kim South Korea 13 242 0.5× 376 0.9× 53 0.5× 78 1.1× 180 3.0× 36 643
Xanthi Tsiafaki Greece 11 571 1.2× 598 1.4× 161 1.6× 23 0.3× 137 2.3× 36 762
Cuiling Zhou China 10 143 0.3× 253 0.6× 104 1.0× 46 0.7× 119 2.0× 11 404
Dayle Hacking Ireland 10 390 0.8× 448 1.1× 165 1.6× 22 0.3× 24 0.4× 19 644
Vincent Fallet France 14 538 1.1× 472 1.1× 103 1.0× 29 0.4× 25 0.4× 45 679
Enjô Hata Japan 9 637 1.3× 395 0.9× 103 1.0× 66 0.9× 39 0.7× 31 864
Zhong-Zhen Guan China 10 157 0.3× 365 0.9× 53 0.5× 111 1.6× 34 0.6× 13 488

Countries citing papers authored by R Cioffi

Since Specialization
Citations

This map shows the geographic impact of R Cioffi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Cioffi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Cioffi more than expected).

Fields of papers citing papers by R Cioffi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R Cioffi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Cioffi. The network helps show where R Cioffi may publish in the future.

Co-authorship network of co-authors of R Cioffi

This figure shows the co-authorship network connecting the top 25 collaborators of R Cioffi. A scholar is included among the top collaborators of R Cioffi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R Cioffi. R Cioffi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Comella, Pasquale, Vincenzo Emanuele Chiurì, Giuseppe De Cataldis, et al.. (2009). Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer. Lung Cancer. 68(1). 94–98. 5 indexed citations
2.
3.
Comella, P., Sebastian T. Palmeri, R Cioffi, et al.. (2006). Cisplatin(P)-including triplets versus P-free doublets in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC): SICOG 0101 randomized trial. Journal of Clinical Oncology. 24(18_suppl). 7103–7103. 1 indexed citations
4.
Comella, P., G. Frasci, B. Massidda, et al.. (2004). Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. British Journal of Cancer. 91(3). 489–497. 54 indexed citations
5.
Belfiore, Giuseppe, et al.. (2004). CT-Guided Radiofrequency Ablation: A Potential Complementary Therapy for Patients with Unresectable Primary Lung Cancer—A Preliminary Report of 33 Patients. American Journal of Roentgenology. 183(4). 1003–1011. 104 indexed citations
6.
Gridelli, Cesare, Antônio Rossi, Emiddio Barletta, et al.. (2002). Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study. Lung Cancer. 36(3). 327–332. 14 indexed citations
7.
Gridelli, Cesare, Luigi Manzione, Francesco Perrone, et al.. (2001). Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study. British Journal of Cancer. 84(1). 38–41. 14 indexed citations
8.
9.
10.
Frasci, G., Nicola Panza, Pasquale Comella, et al.. (1999). Cisplatin, Gemcitabine, and Paclitaxel in Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: A Phase I-II Study. Journal of Clinical Oncology. 17(8). 2316–2316. 48 indexed citations
11.
12.
Gridelli, Cesare, Francesco Perrone, Giovanni Pietro Ianniello, et al.. (1998). Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole.. Journal of Clinical Oncology. 16(4). 1414–1419. 22 indexed citations
13.
Frasci, G., P. Comella, N. Panza, et al.. (1998). Carboplatin–oral etoposide personalised dosing in elderly non-small cell lung cancer patients. European Journal of Cancer. 34(11). 1710–1714. 20 indexed citations
14.
Comella, P., N. Panza, G. Frasci, et al.. (1997). 231 Gemcitabine (GEM)-cisplatin (CDDP)-vinorelbine (VNR) combination in advanced non-small-cell lung cancer (NSCLC). A phase II randomized study. Lung Cancer. 18. 60–60. 6 indexed citations
15.
Gridelli, Cesare, Giovanni Pietro Ianniello, L Brancaccio, et al.. (1997). 212 Carboplatin plus vinorelbine: A new active regimen in extensive small cell lung cancer. Results of a multicenter phase II study. Lung Cancer. 18. 55–55. 5 indexed citations
16.
Frasci, G., P. Comella, Filomena Del Gaizo, et al.. (1997). 141 Carboplatin (CBDCA)-oral etoposide (VP16) personalized dosing in elderly or poor performance status NSCLC patients. Lung Cancer. 18. 38–38. 2 indexed citations
17.
Gridelli, Cesare, L Brancaccio, Franco Perrone, et al.. (1997). Carboplatin plus vinorelbine: A new active regimen in extensive small cell lung cancer. Results of a multicenter phase II study. European Journal of Cancer. 33. S231–S231. 3 indexed citations
18.
Comella, P., N. Panza, G. Frasci, et al.. (1997). Gemcitabine (GEM) — Cisplatin (COOP) — Vinorelbine (VNR) combination in advanced non-small-cell lung cancer (NSCLC). A phase II randomized study. European Journal of Cancer. 33. S229–S229. 1 indexed citations
19.
Comella, P., G. Frasci, N. Panza, et al.. (1996). Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. British Journal of Cancer. 74(11). 1805–1811. 35 indexed citations
20.
Ianniello, Giovanni Pietro, Giuseppe De Cataldis, Pasquale Comella, et al.. (1996). Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: A multicenter randomized clinical trial. Cancer. 78(1). 63–69. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G.P. Nicolella Breakdown of academic impact, for papers by Michèle Natale Breakdown of academic impact, for papers by Swee‐Peng Yap Breakdown of academic impact, for papers by Woo Kun Kim Breakdown of academic impact, for papers by Xanthi Tsiafaki Breakdown of academic impact, for papers by Cuiling Zhou Breakdown of academic impact, for papers by Dayle Hacking Breakdown of academic impact, for papers by Vincent Fallet Breakdown of academic impact, for papers by Enjô Hata Breakdown of academic impact, for papers by Zhong-Zhen Guan
Rankless by CCL
2026